In contrast, novel treatments, such as intranasal oxytocin, vagus nerve stimulation (VNS) and mindfulness-based cognitive therapy (MBCT), ketamine and psychedelic-assisted psychotherapy (PAP), have emerged as promising alternatives for enhancing social cognition and behavior in MDD (26–29). Here, OXT is linked to major depressive disorder.